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Abstract: Huntington’s disease (HD) is an autosomal dominant neurodegenerative disease caused by
the expansion of a CAG trinucleotide repeat encoding an abnormally long polyglutamine tract (PolyQ)
in the huntingtin (Htt) protein. In HD, striking neuropathological changes occur in the striatum,
including loss of medium spiny neurons and parvalbumin-expressing interneurons accompanied by
neurodegeneration of the striosome and matrix compartments, leading to progressive impairment
of reasoning, walking and speaking abilities. The precise cause of striatal pathology in HD is still
unknown; however, accumulating clinical and experimental evidence suggests multiple plausible
pathophysiological mechanisms underlying striatal neurodegeneration in HD. Here, we review
and discuss the characteristic neurodegenerative patterns observed in the striatum of HD patients
and consider the role of various huntingtin-related and striatum-enriched proteins in neurotoxicity
and neuroprotection.
Keywords: Huntington’s disease; huntingtin; striatum; medium spiny neuron; pathophysiology;
striosome; matrix
1. Introduction
Huntington’s disease (HD) is an autosomal dominantly inherited neurodegenerative disorder
characterized by the late onset of gradually worsening motor, cognitive, and psychiatric disturbances [1].
At present, HD is largely untreatable and the mean survival time of individuals with HD is 17–20
years after symptom onset [2]. In HD, a mutation of the protein huntingtin (Htt), which involves
the expansion of a cytosine-adenine-guanine (CAG) repeat encoding an extended glutamine tract
(PolyQ), causes transcriptional dysregulation (Figure 1) resulting in multiple cellular dysfunctions
such as intracellular signaling pathway alterations, protein trafficking defects, synaptic transmission
impairments, proteasome dysfunction, and mitochondrial alterations [3–5]. Htt is highly conserved
among vertebrates and is expressed ubiquitously in the human body [6]. Its highest levels are found in the
brain, where it is expressed in all neurons and glial cells [3]. Despite the ubiquitous expression of mutant
Htt (mHtt) throughout the brain, human pathology has shown that degeneration is specific to certain
neuronal subpopulations affecting the striatum and, to a lesser extent, the cerebral cortex in patients
with HD [4]. In the striatum, a differential involvement of striosome and matrix compartments has been
reported in HD [5–12]. Moreover, ongoing neurodegeneration is preferentially found in medium spiny
neurons (MSNs) and parvalbumin-expressing interneurons in the striatum [13–18]. These findings
indicate that striatal cell type- and compartment-specific vulnerabilities may underlie the etiology
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of striatal pathology in HD [19]. Here, we discuss striatal cell type- and compartment-specific
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Huntingtin  interacts  with  CREB‐binding  protein  (CBP)  and  possibly  with  TATA  box  binding 
protein associated factor (TAF) II 130 and/or TATA box binding protein (TBP). Huntingtin promotes 
transcription of encephalin;  (B) Mutant Huntingtin binds CBP, TAF  II 130 and TBP and prevents 
these  transcription  factors  from  recruitment.  P:  phosphorylation,  TF:  transcription  factor,  CRE: 
cAMP response element, CREB: cAMP response element‐binding protein. 
2. Striatal Anatomy 
In HD,  the striatum has been  identified as  the primarily affected structure, which undergoes 
severe degeneration. As a core structure of basal ganglia circuits, the striatum integrates midbrain 
dopaminergic  inputs  and  neocortical  and  thalamic  glutamatergic  inputs,  and  then  sends 
GABAergic outputs to its target nuclei, such as the globus pallidus and substantia nigra. The striatum 
plays a critical role in processing information related to motor function and reward‐ and goal‐oriented 
behavior.  To  facilitate  the  understanding  of HD  neuropathology, we  briefly  review  normal  striatal 
anatomy (Figure 2). 
2.1. Fundamental Structure 
Respectively,  MSNs  (10–24  μm  in  diameter)  and  medium  aspiny  interneurons  represent 
approximately  90%  and  10%  of  striatal  neurons  in  rodents,  and  approximately  75%  and  25%  of 
striatal neurons  in primates  [20,21]. The  four GABAergic  interneuron  subtypes  found within  the 
striatum express (1) parvalbumin; (2) calretinin; (3) coexpressing nicotinamide adenine dinucleotide 
phosphate  (NADPH)  diaphorase,  nitric  oxide  synthase  (NOS),  neuropeptide  Y  (NPY)  and 
somatostatin;  and  (4)  tyrosine  hydroxylase  (TH)  expressing  interneurons  [20–24]. 
Parvalbumin‐positive interneurons (i.e., “fast‐firing interneurons”) can block or delay the firing of 
more than 100 MSNs [22,25]. NOS‐containing interneurons (i.e., “low‐threshold spike interneurons”) 
release  nitric  oxide  (NO)  via  dopamine  D1/D5  receptor  (D1R/D5R)  activation  and  influence  the 
induction of long‐term depression (LTD) via the cyclic guanosine monophosphate (cGMP) pathway 
[26]. Large aspiny cholinergic interneurons (21–45 μm in diameter) represent 1%–2% of the total cell 
population  in  the  human  striatum  [27].  The  cholinergic  interneurons  play  a  role  in  the 
spatiotemporal selection of convergent inputs to striatal MSNs [28]. 
Figure 1. An example of transcriptional dysregulation by mutant Huntingtin protein. (A) Wild-type
Huntingtin interacts with CREB-binding protein (CBP) and possibly with TATA box binding protein
associated factor (TAF) II 130 and/or TATA box binding protein (TBP). Huntingtin promotes
transcription of encephalin; (B) utant Huntingtin binds CBP, TAF II 130 and TBP and prevents
these transcription factors from recruitment. P: phosphorylation, TF: transcription factor, CRE: cAMP
response element, CREB: cAMP response element-binding protein.
2. Striatal Anatomy
In HD, the striatum has been identified as the primarily affected structure, which undergoes
severe degeneration. As a core structure of basal ganglia circuits, the striatum integrates midbrain
dopaminergic inputs and neocortical and thalamic glutamatergic inputs, and then sends GABAergic
outputs to its target nuclei, such as the globus pallidus and substantia nigra. The striatum plays
a critical role in processing information related to motor function and reward- and goal-oriented
behavior. To facilitate the understanding of HD neuropathology, we briefly review normal striatal
anatomy (Figure 2).
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SNr, substantia nigra reticulata; STN, subthalamic nucleus; GPe, glubus pallidum externus; Th, thalamus. 




globus  pallidus  (GPe)  [30]. Direct  pathway MSNs  express  the D1R  subtype  and muscarinic M4 
receptors and contain  the neurotransmitters dynorphin and  substance P.  Indirect pathway MSNs 
express  the dopamine D2 receptor  (D2R) subtype and adenosine A2A receptors  (A2AR) and contain 
enkephalin  [31,32].  Activation  of  D1R  or  A2AR  increases  cyclic  adenosine  monophosphate 
(cAMP)/protein  kinase  A  (PKA)  signaling,  whereas  activation  of  D2R  decreases  it. 
Phosphodiesterase 10A  (PDE10A)  inhibitors decrease  cAMP/PKA  signaling  in direct and  indirect 
pathway MSNs [33,34]. The direct and indirect pathways converge at the GPi/SNr complex, which 
then  transmits  its GABAergic  outputs  to  the  thalamocortical  pathway  and  brainstem  locomotor 
region, including the pedunculopontine nucleus (PPN) [30]. MSNs receive excitatory glutamatergic 
inputs originating  from  the neocortex  (i.e.,  layers  III  and V)  and  thalamus  (i.e., mainly  from  the 
intralaminar  thalamic  nuclei).  MSNs  possess  10,000–15,000  spines;  however,  corticostriatal 
terminals  form a  small number of  synapses with  individual MSNs. This  indicates  that a massive 
convergence of cortical inputs may occur at this level [22,35]. Synaptic convergence may also apply 
to  thalamic  inputs  since  the  number  of  thalamostriatal  and  corticostriatal  synapses  within  the 
striatum  is  of  a  similar  magnitude  [35].  Striatal  GABAergic  interneurons  receive  cortical  and 




Figure 2. Stri tal structural anatomy and functional circuitry model. (A) A human striatum section
i munostained with anti-Met-enkephalin antibody. (From G to et al. (2015) with permission) [29];
(B) Low-power-magnified microscopic negative image of the caudate nucleus. Asterisks indicate
striosomes (From t al. (2015) with permiss on) [29]; (C) Striatum plays a central role of multiple
feedback and feedforwar regulations in motor processing. Con ectivity diagram showing excitatory
pathways s red and inhibitory pathways as blue. Scale bars: (A) 4 mm; (B) 1 mm. CN, caudate
nucleus; Put, putamen; S, striosomes; M, matrix; C, Cholinergic interneurons; D1, medium spiny
projecti n neurons expressing dopamine D1 recepto s; D2, medium spiny projection neurons expressing
dopamine D2 receptors; SNc, sub tantia nigra compact; GPi, globus pallidus internus; SNr, substantia
nigra reticul ta; STN, s bthalamic nucleus; GPe, glubus pallid m extern s; Th, thalamus.
Striatal SNs send inhibitory GABAergic efferents to their target brain regions. Approximately
half of MSNs project via the “direct pathway” to neurons within the internal globus pallidus (GPi;
i.e., the entopeduncular nucleus in some species) and substantia nigra pars reticulata (SNr) [30].
The rest of the MSNs project via the “indirect pathway” to neurons within the external globus pallidus
(GPe) [30]. Direct pathway MSNs express the D1R subtype and muscarinic M4 receptors and contain
the neurotransmitters dynorphin and substance P. Indirect pathway MSNs express the dopamine
D2 receptor (D2R) subtype and adenosine A2A receptors (A2AR) and contain enkephalin [31,32].
Activation of D1R or A2AR increases cyclic adenosine monophosphate (cAMP)/protein kinase A (PKA)
signaling, whereas activation of D2R decreases it. Phosphodiesterase 10A (PDE10A) inhibitors decrease
cAMP/PKA signaling in direct and indirect pathway MSNs [33,34]. The direct and indirect pathways
converge at the GPi/SNr complex, which then transmits its GABAergic outputs to the thalamocortical
pathway and brainstem locomotor region, including the pedunculopontine nucleus (PPN) [30]. MSNs
receive excitatory glutamatergic inputs originating from the neocortex (i.e., layers III and V) and thalamus
(i.e., mainly from the intralaminar thalamic nuclei). MSNs possess 10,000–15,000 spines; however,
corticostriatal terminals form a small number of synapses with individual MSNs. This indicates that a
massive convergence of cortical inputs may occur at this level [22,35]. Synaptic convergence may also
apply to thalamic inputs since the number of thalamostriatal and corticostriatal synapses within the
striatum is of a similar magnitude [35]. Striatal GABAergic interneurons receive cortical and thalamic
excitatory inputs and provide strong feedforward inhibition (i.e., inhibitory postsynaptic potentials
(IPSPs)) to the proximal dendrites of MSNs [22,36]. This feedforward inhibition is more powerful than
the reciprocal feedback inhibition produced by MSN axons [28].
2.2. Striatal Compartments
The striatum encompasses a three-dimensional labyrinthine structure composed of striosome
and matrix compartments [37–39]. Across mammalian species, striosomes occupy 10%–20% of the
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striatum [40–42]. Striosomes are organized early in embryonic development and receive developmental
cues from dopaminergic inputs originating in substantia nigra pars compacta (SNc) [43–45]. The striosomal
and matrix compartments have MSNs containing D1R and D2R subtypes. In primates, D1Rs are
predominantly localized in striosomes, whereas D2Rs are localized in the matrix [38,46]. Striosomal MSNs
project to the ventral tier of the SNc or its immediate environs [47–49]. Striosomal MSNs also innervate the
habenula, which projects to SNc dopaminergic neurons [50–54]. Reciprocal striosome-SNc innervation
strongly regulates nigral dopaminergic neurons, thereby maintaining critical control over dopaminergic
actions within the striatum [38,55]. Different cortical regions innervate the striosome and matrix
compartments. The prelimbic, infralimbic, caudal orbitofrontal, and pregenual anterior cingulate
cortices innervate striosomes, whereas sensorimotor cortices innervate the matrix [56–63]. These input
fibers as well as striatal MSN dendrites and axons mostly remain within each compartment [64,65].
Large cholinergic interneuron cell bodies are located in the matrix at the edge of the striosome-matrix
boundary [66–71]. The dendrites of cholinergic interneurons spread to both compartments, whereas
their axons are densely distributed within the matrix. Cholinergic interneurons are thought to mediate
inter-compartmental information processing [66,67,70–72]. Neurons of the centromedian-parafascicular
thalamic nuclei innervate and modulate striatal cholinergic interneurons [73].
It is known that reward-related, limbic-based circuits and sensorimotor and associative circuits
are concentrated in the striosome and matrix compartments, respectively [70]. However, differential
activity in the striosomes possibly produces distinct reinforcement-related signals, which give rise to
repetitive behaviors [74,75]. Moreover, the existence of a direct, reciprocal circuit between striosomes
and dopamine-containing SNc neurons suggests that striosomes affect dopamine release within the
matrix through a negative feedback mechanism [19,76–79]. An anatomically- and physiologically-based
computational model of reinforcement learning revealed that the striosomes and matrix are responsible
for motor focusing and scaling, respectively [72].
Striosomal MSNs receive cortical input from the infralimbic cortex, which evaluates and controls
ongoing behaviors [80]. This evaluation cortex sends signals related to responsibility of selected
modules to striosomes. Positive or negative responsible signals are conveyed from striosome into matrix
via cholinergic or, possibly, palvalbumine interneurons [72]. Striosomal MSNs of the striatonigral
pathway release substance P, which depolarizes cholinergic interneurons and induces acetylcholine
release. The released acetylcholine excites matrix interneurons via nicotine receptors and inhibits
matrix MSNs. Striosomal MSNs of the striatofugal pathway release enkephalin, which either directly
or via µ-opioid receptors (MORs) activation, hyperpolarizes cholinergic interneurons in the matrix.
Thus, activation of striosomal MSNs results in the inhibition of acetylcholine release and subsequent
disinhibition of matrix MSNs [70,81]. Cholinergic interneurons are called tonically active neurons
(TANs), and always release acetylcholine into the striatum as background activity [71]. During
sensorimotor learning, dopamine neurons in the SNc exhibit rapid and brief bursts of activity that
coincide with TAN pause phase in response to a conditioned stimulus which predicts reward. TAN pause
response amplifies the release of dopamine only in the targeted area in the matrix compartment [82,83].
The activation of dopamine receptors is required for spike timing-dependent long-term potentiation
(LTP) at striatonigral direct-pathway MSNs and LTD at striatopallidal indirect pathway MSNs in the
matrix compartment [84–86]. TAN pause exerts opposing plasticity effects to these two pathways in
order to enhance the disinhibition of actions by direct-pathway MSNs and to reduce the inhibition of
actions by indirect-pathway MSNs [86]. Thus, the striosomal activation and deactivation in selective
modules might not only enhance the contrasts between modules but serve to limit the spatial extent of
responsibility signaling via a surround inhibition-like mechanism [83]. Dopamine release in the matrix
decides the scaling of the selected modules. Activation of striosomal MSNs inhibits dopamine-containing
SNc neurons and terminates goal-directed behavior by reducing dopamine release in the matrix [70].
Imbalances in the activity of the striosome and matrix compartments could produce changes
in the selection and release of motor and behavioral functions alternatives via inter-compartmental
or striatonigral reciprocal pathways [19,72,74,87]. According to this “compartment” hypothesis, the
Brain Sci. 2017, 7, 63 5 of 25
correlation between specific clinical symptoms and the activity of striatal compartments is important
for understanding basal ganglia disorders, such as HD and dystonia [19,74,79,88,89].
3. Striatal Pathology
HD represents one of the main classes of basal ganglia disorders, as well as Parkinson’s disease and
dystonias. Accumulating evidence suggests that the basal ganglia circuit architecture participates in the
creation of striatal pathology in HD [5–12,89]. Considering the recent advances in our understanding
of the anatomy and functional roles of the striatum, we discuss cell type- and compartment-specific
striatal vulnerabilities in HD (Table 1).
3.1. Wild-Type and mHtt Interacting Proteins
Wild-type Htt, a 347-kDa protein with multiple scaffolds, acts as a major protein interaction
hub and an orchestrator of converging intracellular trafficking and signaling pathways [90,91].
Wild-type Htt has anti-apoptotic properties against starvation, mitochondrial toxins, and mHtt
overexpression [92–94] and is essential for normal embryonic development [95–97]. The anti-apoptotic
effects of wild-type Htt may be associated with the inhibition of pro-apoptotic protein caspase-3 or
pro-caspase-8 through the sequestration of pro-apoptotic protein huntingtin-interacting protein 1
(HIP1) and HIP1 protein interactor (HIPPI) [98,99]. Wild-type Htt also acts as a positive transcriptional
regulator of neuron-restrictive silencer element (NRSE)-regulated genes, such as brain-derived
neurotrophic factor (BDNF) [100,101]. Moreover, wild-type Htt interacts with microtubule-based motor
complex-related proteins (i.e., dynein/dynactin and kinesin), which are essential for the axonal transport
of vesicles [101–105]. Decreased BDNF levels have been demonstrated in cellular and animal models
of HD and patients with HD [106]. A quantitative proteomic analysis revealed that HD pathogenesis
may be linked to changes in Htt interactions with stress granule-associated RNA-binding proteins
(i.e., cytoplasmic activation- and proliferation-associated protein 1 (Caprin-1) and GTPase-activating
protein Src homology 3 (SH3) domain-binding protein 1 (G3BP-1)) [91]. The Caprin-1/G3BP-1 complex
regulates the transport and translation of mRNAs of proteins associated with neuronal synaptic
plasticity, including BDNF [91]. Although BDNF deletion mutant mice had selective loss of olfactory
bulb parvalbumin-containing interneurons via the phospholipase C gamma (PLCγ) pathway, other
calcium-binding, protein-containing neuron populations were unaffected [107].
Autosomal dominant inheritance and other genetic studies strongly indicate that polyglutamine
(polyQ) expansion confers a toxic gain of function to Htt [108–110]. mHtt protein is cleaved by caspases,
calpain, and aspartic endopeptidase, and N-terminal fragments containing the polyQ expansion
are sufficient to produce HD-like abnormal clinical syndromes and intranuclear inclusions in HD
animal models [111–113]. In mice, inhibition of caspase-6-dependent cleavage retains full-length mHtt,
which prevents behavioral and neuropathological dysfunction [114]. Thus, the cleavage of benign
full-length mutant huntingtin into toxic fragments may be a rate-limiting step in HD pathogenesis [90].
The proteolysis and subsequent toxicity of mHtt can also be suppressed with the phosphorylation of
Htt by protein kinase B (Akt), cyclin-dependent kinase 5 (Cdk5), and extracellular signal-regulated
kinase 1 (ERK1) [90,115–117].
mHtt induces mitochondrial dysfunction by reducing adenosine triphosphate (ATP) generation [118],
calcium buffering [119,120], and mitochondrial trafficking [121,122]. A quantitative proteomic analysis
revealed that the most altered interactions occur between Htt and several mitochondrial proteins,
including apoptosis inducing factor, mitochondria associated 1 (AIFM1) [91]. MSNs usually maintain
electrophysiologically low levels of spontaneous discharge, which require a large amount of ATP for the
maintenance of a hyperpolarized state [123]. This mechanism may underlie the vulnerability of MSNs
to mitochondrial dysfunction [110].
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Table 1. Neuroprotective or neurotoxic effects of structure-specific proteins.
Affected Structures or Cell-Types Neuroprotective or Neurotoxic Effects Factors Hypothesized Mechanism
Striatum Neurotoxic or neuroprotective
Predominant expression of Ras homolog
enriched in striatum (Rhes) in the striatum
Neurotoxic: Rhes binds mHtt and increases cytotoxicity or
decreases the autophagic capacity of the striatal neurons.
Neuroprotective: Rhes activates autophagy of mHtt and
induces gene expression promoting mHtt degradation.
MSNs
Neurotoxic
Brain-derived neurotrophic factor (BDNF)
deletion in HD
BDNF is required for survival and dendritic growth of
MSNs preferentially in indirect pathway.
N-methyl D-aspartate receptor subtype 2B
(NR2B) predominant expression in MSNs
High expression of NR2B in MSNs may promote NMDA
excitotoxicity.
Sensitivity to glutamate
MSNs are more sensitive to kainite,
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
receptor (AMPA), N-methyl D-aspartate receptor (NMDA),
and group 1 metabotropic glutamate receptor (mGluR)
agonists than cholinergic interneurons.
Increased NR2B containing extrasynaptic
NMDA receptors
Extrasynaptic NMDA receptors increase the toxic mHtt and
cause dysregulation in p38 mitogen-activated protein
kinase-cAMP response element binding protein
(MAPK-CREB) signaling.
Requirement of higher energy in MSNs Susceptibility for mitochondrial dysfunction induced bymutant-Htt.
Expression level of superoxide dismutases
(SODs)
MSNs contain low level of SODs, which indicates the
vulnerability against oxidative stress.
Neuroprotective
Increased expression of parvalbumin (PVA),
calretinin, and calcium binding proteins
Calcium-buffering effect over excessive calcium-induced
excitotoxicity.
PDE10A deletion Activation of extracellular signal-regulated kinase (ERK),CREB and predominant activation of D2R indirect pathway.
PVAs Neurotoxic
BDNF deletion Blockade of tropomyosin receptor kinase B-phospholipaseCγ (TrkB-PLCγ) pathway by BDNF deletion.
AMPA receptors expression Enrichment in Ca
2+ permeable AMPA receptors induced
calcium-induced excitotoxicity.
Interneurons Neuroprotective Optineurin expression
Optineurin is predominantly expressed in striatal
interneurons and negatively regulates glutamate receptors
via interaction with Htt.
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Table 1. Cont.
Affected Structures or Cell-Types Neuroprotective or Neurotoxic Effects Factors Hypothesized Mechanism
Striosomes Neurotoxic
Phosphodiesterase 10A (PDE-10A) decrease
in cortical regions projecting to striosomes
PDE-10A decrease induces neurodegeneration in cortical
neurons projecting to striosomes.
Dopamine D1R
Enrichment of D1R in striosomes induces
dopamine excitotoxicity.
SOD2 Lower expression level of SOD2 in striosomes inducesvulnerability against oxidative stress.
Olfactory type G-protein α subunit (Gαolf)
Enrichment of Gαolf in striosomes induces D1R and A2AR
mediated neurotoxicity (decreased level of Rhes increases
A2AR/cAMP/protein kinase A (PKA) activity).
Matrix Neuroprotective
Cyclin-dependent kinase 5 (CDK5)
Matrix enrich protein CDK5-pY15 induces phosphorylation
of Htt which results in decrease of toxic effects against
mutant-Htt.
Decrease of calcium diacylglycerol guanine
nucleotide exchange factor 1
(CalDAG-GEF1)
Matrix and MSNs predominant expression pattern
of CalDAG-GEF1 protects them from mutant-Htt
induced toxicity.
Dopamine D2R
Enrichment of D2R in matrix is protective against
dopamine excitotoxicity.
Neuropeptide Y (NPY) Enrichment of NPY in matrix is protective againstglutamate excitotoxicity and microglial activation.
28 kDa calbindin (Calbindin-D28K) Enrichment of Calbindin-D28K in matrix is protectiveagainst excessive Ca2+ influx by calcium-buffering.
Post synaptic density 95 kDa (PSD-95) Matrix enrich protein PSD-95 is protective againstglutamatergic or dopaminergic excitotoxicity.
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Some authors have reported a “dying-back” pattern of neuronal degeneration in HD, which
suggests that deficits in axonal transport underlie the increased vulnerability of projection neurons
to mHtt [108,124,125]. mHtt inhibits axonal transport through the activation of the c-Jun N-terminal
kinase (JNK) pathway and phosphorylation of molecular motor proteins [126].
Wild-type Htt and mHtt interact with transcriptional factors, including cAMP response
element-binding (CREB)-binding protein (CBP), TATA-binding protein (TBP), p53, specificity protein
1 (Sp1), transcriptional repressor element-1 transcription factor/neuron restrictive silencer factor
(REST/NRSF), TAF II 130, and peroxisome proliferator activated receptor γ coactivator 1α (PGC-1α) [127].
However, these proteins are diffusely expressed throughout the brain and do not appear to explain cell
type- or compartment-specific neuronal degeneration.
3.2. Positron Emission Tomography (PET) Imaging Studies
PET imaging studies provide important insights about HD pathogenesis. PET can detect various
molecular changes in HD gene expansion carriers before disease manifestation [128,129]. Currently, one
of the most important biomarkers for patients with HD is PDE10A, which is highly expressed in MSNs,
but not in interneurons [33,130–133]. PDE10A is a dual substrate that regulates cAMP/PKA signaling and
hydrolyzes cAMP and cGMP with an approximately 20-fold higher affinity for cAMP [134]. The inhibition
of PDE10A activates cAMP/ PKA signaling within direct- and indirect-pathway neurons [34]. Previous
PET studies have shown that PDE10A expression decreased in the striatum and pallidum and increased
in the motor thalamus of premanifest HD gene carriers compared to matched healthy controls [135].
PET imaging research using [11C] IMA107 demonstrated a 25%–33% reduction in striatal PDE10A 25
years earlier than predicted symptomatic onset [135,136]. Decreased PDE10A expression was mostly
restricted to the dorsal sensorimotor striatum [135], and lower striatal PDE10A expression was associated
with disease burden and severity [137]. The PDE10A signal decreased by 33%–34% in the striatum
and increased by 35% in the motor thalamus [135]. In HD animal models, PDE10A inhibition reduced
neurodegeneration in striatal and cortical neurons and delayed neurological deficit development [138,139].
PDE10A inhibition causes an up-regulation of cAMP/PKA signaling and CREB phosphorylation and
increases BDNF expression in striatal neurons [138]. Moreover, PDE10A inhibition has a greater
facilitatory effect on the corticostriatal synaptic activity of indirect-pathway neurons than on that of
direct-pathway neurons [140].
Increased microglial activation begins at approximately 15–20 years before symptom
manifestation [141–143]. Moreover, several studies have reported decreases in D2Rs, brain metabolism,
and cortical gray and white matter volume at approximately 10 years before disease manifestation [128,129].
In premanifest HD gene carriers, D1Rs and D2Rs are significantly reduced by 25%–50% [144,145]. At the
premanifest stage, the mean annual decline rate is 2% for D1Rs and 4%–6.3% for D2Rs [144,146].
3.3. Striatum-Predominant Neurodegeneration in HD
Along the sagittal axis of the brain, the caudal caudate nucleus (CN) and putamen show greater
neuronal loss than the rostral CN and putamen. Moreover, along the coronal axis of the brain, the dorsal
and medial striatum are more degenerated than the ventral and lateral striatum [3]. Magnetic resonance
imaging (MRI) studies have shown the same striatal atrophy gradients [147,148]. In the early stages of
HD when chorea is most apparent, there is a preferential loss of neurons from the indirect pathway
projecting to the GPe [13]. The increased frequency of movement release associated with the early
and selective involvement of indirect-pathway neurons may explain the genesis of chorea in HD.
This notion is supported by evidence obtained from a transgenic mouse model study in which
indirect-pathway neurons bearing D2Rs were selectively ablated [149].
Wild-type Htt and mHtt are expressed in the brain without significant inter-regional variation,
which suggests that the pathogenic process is not a direct effect of mHtt toxicity [150,151]. Increased
glutamine tract lengths of mHtt are more prominent in the striatum than in the cortex [152,153].
Although striatal vulnerability is correlated with the size of the CAG repeat expansion in the Htt
Brain Sci. 2017, 7, 63 9 of 25
located on the short arm of chromosome 4 [154], the mechanisms causing this increasing vulnerability
of the striatum are yet to be elucidated [3].
In patients with HD, striatal vulnerability may be associated with reduced corticostriatal input
due to impairment of BDNF, an important neuromodulator and trophic factor. Wild-type Htt positively
regulates BDNF, whereas mHtt fails to regulate BDNF [155]. BDNF is reduced in the brains of mice
and humans with HD. This reduction in BDNF may be attributable to mHtt-induced reduction of
anterograde axonal transport within cortical neurons [101,103,156], decreased BDNF endocytosis by
MSNs [157], or both of these mechanisms [110]. BDNF supports MSN survival and is required for the
dendritic growth of striatal neurons [106,158]. Interestingly, decreased BDNF levels induce selective
neuronal degeneration in enkephalinergic, indirect-pathway MSNs [159].
Rhes is a guanine nucleotide-binding protein that may affect small ubiquitin-like modifier (SUMO)
modification and preferentially interact with mHtt [160]. Rhes is predominantly expressed in the
striatum and, to lesser extent, in other forebrain areas affected by HD. Htt and Rhes interactions
may underlie the regional specificity of HD [160,161]. Rhes binds to mHtt and acts as a SUMO E3
ligase to stimulate sumoylation of mHtt, which increases mHtt toxicity [160,162]. In a toxin model of
HD, the deletion of Rhes dramatically reduced striatal degeneration and motor dysfunction [163,164].
Moreover, Rhes normally binds to and activates the mechanistic target of rapamycin (mTOR), which
inhibits autophagy (i.e., lysosomal degradation); however, in cells with robust autophagy, Rhes
activates autophagy via inhibitory binding of Bcl-2 to Beclin-1 [165]. Proteasomal degradation of mHtt
prevents cytotoxicity early in life; however, when proteasomal function is compromised by normal
aging, autophagy is required. Thus, functional changes associated with aging may explain delayed
symptom onset in HD [165,166]. In the striatum, Rhes and mHtt interactions augment cytotoxicity and
diminish the autophagic capacity of the neuron [165]. On the other hand, other authors postulate that
Rhes is a neuroprotective protein against mHtt-induced neuronal cell death. Rhes levels are reduced
in HD patient caudate nucleus and HD mouse model striatum [167,168]. siRNA knockdown of Rhes
exacerbates striatal atrophy and behavioral phenotypes in transgenic HD mice [169]. In addition,
restoring Rhes alleviates motor deficits and brain pathology in HD mice by activating autophagy
of mHtt via increasing Beclin-1, and by altering mTORC1-induced gene expressions implicated in
promoting mHtt degradation [168]. mHtt binds both Rhes and mTOR, which reduces the available
level of these proteins for intact signaling. Concomitant loss of Rhes and mTOR may render the
striatum more vulnerable to early degeneration in HD [168].
3.4. Cell Type-Specific Vulnerability
In HD, the most striking neuropathology is the primary and progressive degeneration of MSNs
and parvalbumin interneurons and relative sparing of cholinergic and NOS-containing interneurons in
the striatum [12–14,18,21,170,171]. Htt and its mRNA are widely expressed in the brain; however, they
are less abundant in the striatum compared to many brain regions [150,172–175]. In HD, the amount
of Htt and its mRNA present in surviving striatal neurons is not obviously altered, which suggests
that Htt expression is not associated with cell type-specific loss in the striatum [175–179]. Moreover,
mHtt overexpression may promote functional abnormalities in other neurons besides MSNs, which
suggests that MSN vulnerability is not specific to mHtt [180,181].
3.4.1. Glutamate Excitotoxity
In HD, glutamate excitotoxicity within the striatum has been proposed as a possible cause of
MSN vulnerability [182–187]. Cell type-specific loss of neurons is a hallmark of striatal excitotoxic
lesions [188]. Previous studies have shown a reduction of N-methyl-D-aspartate (NMDA) and
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors in the CN and cerebral
cortex of symptomatic patients [189,190] and animal models [191,192] with HD. In animal models
of HD, decrease of striatal glutamate receptors and glutamate release has been reported [193,194].
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In contrast to symptomatic HD models, AMPA and NMDA currents in pre-symptomatic animal
models of HD increased only during the early stages and decreased during a later stage [195–197].
NMDA glutamate receptors form heteromeric dimers of NR1 and NR2 subunits [198]. The NR2B
and NR2D subunits are highly expressed in MSNs and striatal interneurons, respectively [199,200].
NR1 subunits are essential for NMDA receptor function. When NR1 is heteromerized with NR2, the
permeability of the NMDA channel increases over 100-fold and deactivation time also increases [201].
This differential expression pattern may explain the increased vulnerability of MSNs [110]. The balance
between synaptic and extrasynaptic NMDA receptors activity may underlie the determination in
neuronal cell survival in HD [202–205]. Synaptic NMDA receptor activity promotes formation of
nontoxic mHtt aggregation [202]. Increased NR2B subunit containing extrasynaptic NMDA receptor
expression, and current and associated reduction in CREB activation in HD mouse striatum, correlate
with mutation severity [203,204]. Activation of extrasynaptic NMDA receptors increases the soluble and
toxic mHtt, in part by increasing Rhes expression [202]. Increased toxic mHtt binds to CBP and causes
transcriptional deregulation of the CREB-PGC-1α cascade [202]. NR2B subunit containing extrasynaptic
NMDA receptors also cause dysregulation in p38 MAPK and CREB signaling in HD model mice [205].
Calabresi et al. reported that MSNs were more sensitive than cholinergic interneurons to group I
metabotropic glutamate receptor agonists and ionotropic glutamate receptor agonists, such as kainite,
AMPA, and NMDA [184,185]. Moreover, in HD, increased expression of the calcium-binding proteins
parvalbumin and calretinin is positively associated with interneuron survival [206]. Parvalbumin and
calretinin exert calcium-buffering effects in response to excessive calcium-induced excitotoxicity and
are thought to be neuroprotective and important for the survival of interneurons [207,208]. However,
the enrichment of calcium-permeable AMPA receptors in parvalbumin interneurons may be a potential
pathogenic mechanism [209]. Optineurin is preferentially distributed in interneurons within the naïve
mouse striatum [210]. Through its interactions with postsynaptic density protein 95 (PSD-95) or
optineurin, wild-type Htt becomes a negative regulator of glutamate receptors [211,212]. This indicates
that, with PSD-95 or optineurin, wild-type Htt could exert neuroprotective effects against excessive
glutamatergic input [210].
3.4.2. Mitochondrial Dysfunction
In post-mortem studies of HD brain tissue, decreased activity in mitochondrial respiratory chain
complexes II, III, and IV was found [213]. By maintaining a hyperpolarized state requiring high amounts
of energy, striatal MSNs usually remain electrophysiologically silent [123,214]. The unique energy
requirements of MSNs may be associated with their susceptibility to mitochondrial dysfunction [215].
Cholinergic interneurons are enriched in the superoxide free radical scavengers superoxide dismutase 1
and 2 (SOD1 and SOD2), whereas MSNs contain low levels of these enzymes [216]. Although oxidative
damage is rarely reported in early-stage HD, it may be a major mechanism during later disease
progression [217].
3.5. Striatal Compartment-Specific Degeneration
3.5.1. Striosome vs. Matrix Neurodegeneration
Differential neurodegeneration of the striatal compartments has been implicated in HD [5–11,218].
In the early stage of the disease, a preferential loss of striosomal neurons that gradually spreads to
matrix neurons has been reported [5–9]. However, some studies reported preferential loss of matrix
neurons [9–12]. Tippet et al. demonstrated that HD cases with pronounced striosomal neuron loss
had shorter CAG repeat lengths than cases with matrix neuron loss or mixed compartmental loss [9].
Moreover, individuals with pronounced striosomal neuron loss did not die during the early stages
of disease progression and exhibited more severe mood disturbances [9]. There is a strong inverse
relationship between mHtt CAG repeat size and age of onset [151,219] and death [220]. However, disease
duration does not vary between individuals with short or long CAG repeats [220]. These results
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potentially indicate that individuals with preferential matrix neuron loss have relatively rapid disease
progression. The preferential neurodegeneration of striosomal MSNs has been reported in HD, as
in cerebral ischemia and X-linked dystonia-parkinsonism, the other transcriptional dysregulation
syndrome [8,79,184,188,221]. The preferential loss of MSNs in the striosome compartment relative
to those in the matrix compartment is thought to be an important factor in the development of
abnormal involuntary movements (e.g., dystonias) [19,79,88,188,222]. Tippet found that, in cases with
preferential striosome or matrix neurodegeneration, there was no difference in the severity of motor
disturbance, even at the end stage of the illness [9]. Neurons within the matrix compartment project
from the striatum to the basal ganglia circuitry and are responsible for motor scaling [72]. Consequently,
instead of producing chorea, matrix neurodegeneration only induces multiple system atrophy of the
parkinsonian type [223]. The striosome compartment is organized early in embryonic development and
occupies 10%–20% of the striatum across mammalian species [40–42]. If striosomal neurodegeneration
reflects the D1R decrease observed in striatal PET studies, the annual striosomal degeneration rate is
estimated to exceed that of D2Rs at the premanifest stage by 2–3-fold. We hypothesize that individuals
with pronounced matrix neurodegeneration had prior striosomal neurodegeneration to some extent,
and rapid matrix neuron loss may produce the matrix-predominant neurodegeneration pattern. Since
the striosome and matrix compartments are responsible for motor focusing and motor scaling [72],
striosomal neurodegeneration is sufficient to induce abnormal movements. Matrix D1Rs are required
for the maintenance of exaggerated movements, and neurodegeneration of matrix D2Rs reinforces
this enlargement in movements as well. Rapid matrix neurodegeneration may be associated with
mHtt-related neurotoxicity. Since autopsied brains are usually acquired at the end stage of the disease,
it may be useful to investigate the striatal neuropathology of animal models. In a study of a transgenic
rodent model of HD, preferential loss of striosomal neurons was reported [224]. Moreover, a PET study
of early premanifest HD gene carriers revealed that extra-striatal PDE10A expression decreased by
25% and 50% in the insular cortex and occipital fusiform gyrus, respectively [136]. These cortical areas
are associated with cognitive and limbic functions and are striosome-related areas [225].
3.5.2. Dopamine Excitotoxicity-Induced Striosomal Cell Vulnerability
Preferential striosomal neurodegeneration may disinhibit dopaminergic neurons in the SNc via
the striosomal pathway [19]. It is hypothesized that, in early-stage HD, striatal dopamine levels are
up-regulated, which induces hyperkinetic movement disorder and striatal dopamine excitotoxicity [226].
This hypothesis is supported by evidence that anti-dopaminergic agents are effective suppressants
of abnormal hyperkinetic movements in patients with HD [227]. A study quantifying dopamine and
dopamine metabolite levels in autopsied HD human brains found increased dopamine levels in the
striatum and substantia nigra [228]. These results were corroborated by a study that found increased
dopamine metabolite levels in the cerebrospinal fluid of patients with HD [229]. TH, the rate-limiting
enzyme for catecholamine synthesis, is highly concentrated in the neostriatum [230]. In HD, increased
TH activity corresponds to increased cellular dopamine levels and neurotoxicity [231,232]. In a study of
R2/6 transgenic mice, TH activity increased during early-stage HD and significantly decreased at a
later stage [230]. In another previous study, dopamine levels in the CN and putamen of patients with
HD were normal [233]; however, since striatal D1Rs and D2Rs were decreased, a relative increase in
dopamine transmission could occur at the network level. Dopamine overflow in the striatum also
results in a relative increase in striatal glutamatergic inputs.
Preferential striosomal MSN degeneration may disrupt motor focusing via the acetylcholine-
mediated transcompartmental pathway and increase motor scaling via increased striosomal
pathway-mediated dopaminergic input [72]. In HD, excessive activity of the dopamine and glutamate
pathways may exert neurotoxic effects on the striatum [161,227]. Generally, D1R overstimulation exerts
a neurotoxic effect, whereas D2R stimulation can be neuroprotective [234]. The D1R and G-protein α
subunit (Gαolf) are preferentially expressed in the striosome compartment, which may be associated
with striosomal vulnerability [87,235]. Rhes normally reduces agonist-stimulated cAMP by binding to
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Gαi [236,237] or inhibiting Gs/olf-mediated signaling [237–240]. However, Rhes is not involved in the
D2R/Gαi–mediated adenylyl cyclase inhibition and does not directly interact with D1R [237]. Recent
study suggests that decreased level of Rhes increases A2AR/cAMP/PKA activity selectively under
the conditions of dopamine/adenosine-related drug challenge in A2AR/D2R-expressing MSNs [240].
A2AR is evenly distributed in the striatum [87], hence preferential striosomal expression of Gαolf
may decide excitatory neurotoxic effects of A2AR/cAMP/PKA signaling in A2AR/D2R-expressing
MSNs [241].
3.5.3. The NPY System Exerts Protective Effects on the Matrix Compartment in HD
In HD, early-stage preferential striosomal neurodegeneration is followed by late-stage neuron
loss in the surrounding matrix [5–8,10,79,188]. In patients with HD, the number of NPY-positive cells
increases in the striatum [188,242]. NPY exerts an inhibitory effect on glutamate release and microglial
activation [243]. Interestingly, NPY fibers are largely distributed in the matrix compartment of the
striatum. This suggests that NPY exerts greater neuroprotective effects against excitotoxicity induced
by excessive glutamate and microglial activation in the matrix compared to the striosomes [188].
3.5.4. Other Proteins May Underlie the Differential Excitotoxicity between Striosome and
Matrix Compartments
Enhanced dopaminergic and glutamatergic inputs to the striatum may cause neurotoxicity
due to impaired calcium-buffering capacity and subsequent neurodegeneration of the matrix
compartment [225,244–246]. In HD, increased expression of calcium-binding protein calbindin-D28K
is positively associated with interneuron survival [206]. Calbindin-D28K is predominantly found in
the matrix and thought to exert neuroprotective effects that promote calcium-buffering in response to
excessive calcium-induced excitotoxicity [207,208]. Crittenden et al. found that calcium diacylglycerol
guanine nucleotide exchange factors (CalDAG-GEFs), which are striatum-enriched calcium and
diacylglycerol binding proteins, are severely down-regulated in the R6/2 mouse model of HD
and post-mortem striatal tissues from patients with HD [89]. Knockdown of matrix-predominant
CalDAG-GEF1 protein expression protects against the deleterious effects of mHtt overexpression and
may be a compensatory response to MSN vulnerability to mHtt expression [89]. Media et al. reported
lower SOD2 expression levels in the striosomal compartment compared to the matrix compartment.
This may be associated with preferential striosomal vulnerability to oxidative stress-induced free
radical generation [216].
Wild-type Htt is a negative regulator of glutamate receptor and D1R activities via interaction
with PSD-95 [211]. This indicates that wild-type Htt and PSD-95 could exert neuroprotective effects
against excessive glutamatergic and dopaminergic inputs. PSD-95 not only negatively regulates NMDA
glutamate signaling, but also dopamine D1 signaling at post-synaptic transmission sites. These PSD-95
activities may also exert protective effects against excessive glutamatergic and dopaminergic inputs
in the matrix compartment [247]. PSD-95 is predominantly distributed in the matrix relative to the
striosomes, which suggests that striosomes are more vulnerable to glutamatergic or dopaminergic
excitotoxicity [247]. By phosphorylating dopamine and cAMP-dependent protein kinase, Cdk5 also
acts as a negative regulator of postsynaptic dopaminergic signaling [248] and may exert protective
effects against excessive dopamine. Activated Cdk5 (i.e., Cdk5 with phosphorylation at the tyrosine
15 residue) is a matrix-enriched protein and may exert neuroprotective effects within the matrix
compartment [249].
4. Conclusions
When examining pathophysiological changes in patients with Huntington’s disease, several
factors should be taken into consideration. For several reasons, in early-stage HD, preferential striatal
MSN neurodegeneration and predominant striosomal neuron loss occur due to susceptibility, not
specificity. This implies that it is important to examine the differences between MSNs and non-MSN
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neurons or between the striosomal and matrix compartments of the striatum. Structure-specific protein
expression may be a key contributor to the neurodegenerative phenomena of the HD brain (Table 1).
These proteins exert neurotoxic or neuroprotective functions against oxidative stress, glutamatergic or
dopaminergic excitotoxicity, and dysregulation in autophagy or axonal transport. MSNs are enriched in
NR2B and deficient in optineurin, which may explain their susceptibility to glutamatergic excitotoxicity.
Moreover, the higher energy requirements and low SOD expression of MSNs may be associated
with their vulnerability to mitochondrial dysfunction. Striosomes are enriched in D1R and Gαolf
and deficient in calbindin-D28K, PSD-95, NPY, and CDK5-pY15. Consequently, striosomal MSNs
may be more susceptible to D1R- and glutamate-mediated excitotoxicity than matrix MSNs. A better
understanding of the pathogenic mechanisms by which neurodegeneration primarily and progressively
occurs in the striatum in HD patients can be achieved with further in vivo and in vitro studies on
striatal cell type- and compartment-specific vulnerability to neurotoxicity caused by mHtt.
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